Into treatment of idiopathic inflammation of the gut cytokine or their antagonist entered less than 5 year ago and they extended the range of classical medicamentoua treatment with aminoalicylate , cortico teroid and immunosuppresive . The theoretical model of their therapeutic application pertained to the blocking of anti-inflammatory cytokine (IL-1, IL-6, IL-8, TNF alpha), the u e of immunomodulating cytokine (IL-2,IL-6, IL-8, IL-9) imilarly as the therapeutic administration of cytokine with a predominant growth and regulating activity (CSF, TGFalpha, TGFbeta, ODGF,IL-10,IL-11, IL-12). The range is upplemented by ICAM, VCAM antibody oligonucleotide and PAG antagonist . The tage of animal experiment was so far pased only by rhuIL-10, antiIL-2 and PAF antagonist . The only anticytokine which within the record time of 10 year found clinical indication in Crohn´ disease , is antiTNF.

        Key words: Idiopathic inflammation of the gut - Crohn´ disease - Ulcerative colitis - CSF (Colony Stimulating Factor), TGF (Tran forming Growth Factor) - PAF (Platelet Activating Factor)-TNF ( Tumour Necro i Factor) - Cytokines